Table 3: Open in new tab Five-year...

Clinical outcome	Oral hypoglycaemic agents (n = 270)	Insulin (n = 452)	Oral vs insulin treatment	Interaction P-value^a
MACCE^b	26.4% (31)	40.4% (56)	0.022	32.6% (28)	56.2% (49)	0.002	0.37	0.023	0.34
All-cause death/stroke/myocardial infarction	17.7% (21)	18.8% (26)	0.92	21.0% (18)	32.1% (28)	0.091	0.65	0.018	0.25
All-cause death	12.0% (14)	16.6% (23)	0.32	14.0% (12)	24.1% (21)	0.082	0.70	0.15	0.53
Cardiac death	6.0% (7)	8.9% (12)	0.42	7.1% (6)	18.8% (16)	0.023	0.79	0.030
Stroke	5.2% (6)	1.6% (2)	0.094	4.0% (3)	5.2% (4)	0.65	0.56	0.13	0.17
Myocardial infarction	5.1% (6)	7.5% (10)	0.49	5.7% (5)	11.6% (9)	0.23	0.83	0.34	0.76
Repeat revascularization	12.0% (13)	29.9% (40)	<0.001	18.1% (15)	44.3% (35)	0.001	0.19	0.063	>0.99
PCI	12.9% (78)	24.8% (33)	0.004	15.0% (12)	34.6% (27)	0.005	0.41	0.21
CABG	1.1% (7)	7.0% (9)	0.020	3.3% (3)	11.6% (9)	0.064	0.19	0.23
Graft occlusion/stent thrombosis	5.7% (6)	3.2% (4)	0.35	2.5% (2)	8.6% (7)	0.081	0.30	0.072	0.046

Clinical outcome

Oral hypoglycaemic agents (n = 270)

Insulin (n = 452)

Oral vs insulin treatment

Interaction P-value^a

CABG (n = 128)

PCI (n = 142)

P-value

CABG (n = 93)

PCI (n = 89)

P-value

P-value (CABG)

P-value (PCI)

MACCE^b

26.4% (31)

40.4% (56)

0.022

32.6% (28)

56.2% (49)

0.002

0.37

0.023

0.34

All-cause death/stroke/myocardial infarction

17.7% (21)

18.8% (26)

0.92

21.0% (18)

32.1% (28)

0.091

0.65

0.018

0.25

All-cause death

12.0% (14)

16.6% (23)

0.32

14.0% (12)

24.1% (21)

0.082

0.70

0.15

0.53

Cardiac death

6.0% (7)

8.9% (12)

0.42

7.1% (6)

18.8% (16)

0.023

0.79

0.030

Stroke

5.2% (6)

1.6% (2)

0.094

4.0% (3)

5.2% (4)

0.65

0.56

0.13

0.17

Myocardial infarction

5.1% (6)

7.5% (10)

0.49

5.7% (5)

11.6% (9)

0.23

0.83

0.34

0.76

Repeat revascularization

12.0% (13)

29.9% (40)

<0.001

18.1% (15)

44.3% (35)

0.001

0.19

0.063

>0.99

PCI

12.9% (78)

24.8% (33)

0.004

15.0% (12)

34.6% (27)

0.005

0.41

0.21

CABG

1.1% (7)

7.0% (9)

0.020

3.3% (3)

11.6% (9)

0.064

0.19

0.23

Graft occlusion/stent thrombosis

5.7% (6)

3.2% (4)

0.35

2.5% (2)

8.6% (7)

0.081

0.30

0.072

0.046

Clinical outcome	Oral hypoglycaemic agents (n = 270)	Insulin (n = 452)	Oral vs insulin treatment	Interaction P-value^a
MACCE^b	26.4% (31)	40.4% (56)	0.022	32.6% (28)	56.2% (49)	0.002	0.37	0.023	0.34
All-cause death/stroke/myocardial infarction	17.7% (21)	18.8% (26)	0.92	21.0% (18)	32.1% (28)	0.091	0.65	0.018	0.25
All-cause death	12.0% (14)	16.6% (23)	0.32	14.0% (12)	24.1% (21)	0.082	0.70	0.15	0.53
Cardiac death	6.0% (7)	8.9% (12)	0.42	7.1% (6)	18.8% (16)	0.023	0.79	0.030
Stroke	5.2% (6)	1.6% (2)	0.094	4.0% (3)	5.2% (4)	0.65	0.56	0.13	0.17
Myocardial infarction	5.1% (6)	7.5% (10)	0.49	5.7% (5)	11.6% (9)	0.23	0.83	0.34	0.76
Repeat revascularization	12.0% (13)	29.9% (40)	<0.001	18.1% (15)	44.3% (35)	0.001	0.19	0.063	>0.99
PCI	12.9% (78)	24.8% (33)	0.004	15.0% (12)	34.6% (27)	0.005	0.41	0.21
CABG	1.1% (7)	7.0% (9)	0.020	3.3% (3)	11.6% (9)	0.064	0.19	0.23
Graft occlusion/stent thrombosis	5.7% (6)	3.2% (4)	0.35	2.5% (2)	8.6% (7)	0.081	0.30	0.072	0.046

Table 3:

Open in new tab

Five-year clinical outcomes according to diabetes treatment

Clinical outcome	Oral hypoglycaemic agents (n = 270)			Insulin (n = 452)			Oral vs insulin treatment		Interaction P-value^a
Clinical outcome	CABG (n = 128)	PCI (n = 142)	P-value	CABG (n = 93)	PCI (n = 89)	P-value	P-value (CABG)	P-value (PCI)	Interaction P-value^a
MACCE^b	26.4% (31)	40.4% (56)	0.022	32.6% (28)	56.2% (49)	0.002	0.37	0.023	0.34
All-cause death/stroke/myocardial infarction	17.7% (21)	18.8% (26)	0.92	21.0% (18)	32.1% (28)	0.091	0.65	0.018	0.25
All-cause death	12.0% (14)	16.6% (23)	0.32	14.0% (12)	24.1% (21)	0.082	0.70	0.15	0.53
Cardiac death	6.0% (7)	8.9% (12)	0.42	7.1% (6)	18.8% (16)	0.023	0.79	0.030
Stroke	5.2% (6)	1.6% (2)	0.094	4.0% (3)	5.2% (4)	0.65	0.56	0.13	0.17
Myocardial infarction	5.1% (6)	7.5% (10)	0.49	5.7% (5)	11.6% (9)	0.23	0.83	0.34	0.76
Repeat revascularization	12.0% (13)	29.9% (40)	<0.001	18.1% (15)	44.3% (35)	0.001	0.19	0.063	>0.99
PCI	12.9% (78)	24.8% (33)	0.004	15.0% (12)	34.6% (27)	0.005	0.41	0.21
CABG	1.1% (7)	7.0% (9)	0.020	3.3% (3)	11.6% (9)	0.064	0.19	0.23
Graft occlusion/stent thrombosis	5.7% (6)	3.2% (4)	0.35	2.5% (2)	8.6% (7)	0.081	0.30	0.072	0.046

Clinical outcome	Oral hypoglycaemic agents (n = 270)			Insulin (n = 452)			Oral vs insulin treatment		Interaction P-value^a
Clinical outcome	CABG (n = 128)	PCI (n = 142)	P-value	CABG (n = 93)	PCI (n = 89)	P-value	P-value (CABG)	P-value (PCI)	Interaction P-value^a
MACCE^b	26.4% (31)	40.4% (56)	0.022	32.6% (28)	56.2% (49)	0.002	0.37	0.023	0.34
All-cause death/stroke/myocardial infarction	17.7% (21)	18.8% (26)	0.92	21.0% (18)	32.1% (28)	0.091	0.65	0.018	0.25
All-cause death	12.0% (14)	16.6% (23)	0.32	14.0% (12)	24.1% (21)	0.082	0.70	0.15	0.53
Cardiac death	6.0% (7)	8.9% (12)	0.42	7.1% (6)	18.8% (16)	0.023	0.79	0.030
Stroke	5.2% (6)	1.6% (2)	0.094	4.0% (3)	5.2% (4)	0.65	0.56	0.13	0.17
Myocardial infarction	5.1% (6)	7.5% (10)	0.49	5.7% (5)	11.6% (9)	0.23	0.83	0.34	0.76
Repeat revascularization	12.0% (13)	29.9% (40)	<0.001	18.1% (15)	44.3% (35)	0.001	0.19	0.063	>0.99
PCI	12.9% (78)	24.8% (33)	0.004	15.0% (12)	34.6% (27)	0.005	0.41	0.21
CABG	1.1% (7)	7.0% (9)	0.020	3.3% (3)	11.6% (9)	0.064	0.19	0.23
Graft occlusion/stent thrombosis	5.7% (6)	3.2% (4)	0.35	2.5% (2)	8.6% (7)	0.081	0.30	0.072	0.046

Data are Kaplan–Meier time-to-event estimates expressed as % (n); log-rank P-value.

CABG: coronary artery bypass grafting; MACCE: major adverse cardiac or cerebrovascular events; PCI: percutaneous coronary intervention.

^aBinary logistic regression interaction term for diabetes status by treatment arm.

^bMACCE consists of all-cause death, stroke, myocardial infarction or repeat revascularization (CABG or PCI) in any vessel.

This Feature Is Available To Subscribers Only